{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T02:19:15Z","timestamp":1789265955426,"version":"build-2803163510"},"reference-count":52,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplant Immunology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.trim.2022.101774","type":"journal-article","created":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T02:40:48Z","timestamp":1670985648000},"page":"101774","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens"],"prefix":"10.1016","volume":"76","author":[{"given":"A.","family":"Chiodo Ortiz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Petrossian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Addonizio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Hsiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Plews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Conti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Ortiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4","key":"10.1016\/j.trim.2022.101774_bb0005","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJMoa1506027","article-title":"Belatacept and long-term outcomes in kidney transplantation","volume":"374","author":"Vincenti","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.trim.2022.101774_bb0010","doi-asserted-by":"crossref","first-page":"2106","DOI":"10.1111\/ajt.12795","article-title":"A systematic review of conversion from calcineurin inhibitor to mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients","volume":"14","author":"Lim","year":"2014","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.trim.2022.101774_bb0015","doi-asserted-by":"crossref","first-page":"3252","DOI":"10.1681\/ASN.2021050628","article-title":"Conversion from calcineurin inhibitor to belatacept-based maintenance immunosuppression in renal transplant recipients: a randomized phase 3b trial","volume":"32","author":"Budde","year":"2021","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.trim.2022.101774_bb0020","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1111\/j.1600-6143.2011.03976.x","article-title":"Summary of the US FDA approval of belatacept","volume":"12","author":"Archdeacon","year":"2012","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2022.101774_bb0025","article-title":"Belatacept for kidney transplant recipients","volume":"Issue 11","author":"Masson","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.trim.2022.101774_bb0030","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1111\/j.1600-6143.2009.03005.x","article-title":"A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT study)","volume":"10","author":"Vincenti","year":"2010","journal-title":"Am. J. Transplant."},{"key":"10.1016\/j.trim.2022.101774_bb0035","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/j.1600-6143.2011.03785.x","article-title":"Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients","volume":"12","author":"Vincenti","year":"2012","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.trim.2022.101774_bb0040","first-page":"239","article-title":"Survival of post-transplant lymphoproliferative disorder after kidney transplantation in patients under rapamycin treatment","volume":"15","author":"Ashrafi","year":"2021","journal-title":"Int. J. Hematol. Oncol. Stem Cell Res."},{"issue":"1","key":"10.1016\/j.trim.2022.101774_bb0045","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1080\/13696998.2021.1915793","article-title":"Cost burden of post-transplant lymphoproliferative disease following kidney transplants in Medicare-eligible patients by survival status","volume":"24","author":"Hart","year":"2021","journal-title":"J. Med. Econ."},{"issue":"2","key":"10.1016\/j.trim.2022.101774_bb0050","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1007\/s12288-019-01182-x","article-title":"Post transplant lymphoproliferative disorder","volume":"36","author":"Gupta","year":"2020","journal-title":"Ind. J. Hematol. Blood Transfus."},{"issue":"2","key":"10.1016\/j.trim.2022.101774_bb0055","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ajh.21911","article-title":"Risk factors for early-onset and late-onset post-transplant lymphoproliferative disorder in kidney recipients in the United States","volume":"86","author":"Quinlan","year":"2011","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.trim.2022.101774_bb0060","series-title":"WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues","year":"2017"},{"issue":"2","key":"10.1016\/j.trim.2022.101774_bb0065","doi-asserted-by":"crossref","first-page":"286","DOI":"10.2215\/CJN.15971020","article-title":"Long-term infectious complications of kidney transplantation","volume":"17","author":"Agrawal","year":"2022","journal-title":"Clin. J. Am. Soc. Nephrol."},{"issue":"2","key":"10.1016\/j.trim.2022.101774_bb0070","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1046\/j.1600-6143.2003.00325.x","article-title":"Lymphomas after solid organ transplantation: a collaborative transplant study report","volume":"4","author":"Opelz","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"4","key":"10.1016\/j.trim.2022.101774_bb0075","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1111\/bjh.14083","article-title":"Iatrogenic immunosuppression and risk of non-Hodgkin lymphoma in solid organ transplantation: a population-based cohort study in Australia","volume":"174","author":"Na","year":"2016","journal-title":"Br. J. Haematol."},{"issue":"22","key":"10.1016\/j.trim.2022.101774_bb0080","doi-asserted-by":"crossref","first-page":"1977","DOI":"10.2146\/ajhp120770","article-title":"Risk of posttransplant lymphoproliferative disorder associated with use of belatacept","volume":"70","author":"Martin","year":"2013","journal-title":"Am. J. Health Syst. Pharm."},{"issue":"7","key":"10.1016\/j.trim.2022.101774_bb0085","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/ajt.16423","article-title":"Swiss Transplant Cohort Study (STCS). Association of antiviral prophylaxis and rituximab use with posttransplant lymphoproliferative disorders (PTLDs): a nationwide cohort study","volume":"21","author":"Walti","year":"2021","journal-title":"Am. J. Transplant."},{"issue":"7","key":"10.1016\/j.trim.2022.101774_bb0090","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1148\/rg.347130130","article-title":"Posttransplantation lymphoproliferative disease: proposed imaging classification","volume":"34","author":"Camacho","year":"2014","journal-title":"Radiographics."},{"issue":"Suppl. 1","key":"10.1016\/j.trim.2022.101774_bb0095","doi-asserted-by":"crossref","first-page":"i27","DOI":"10.1093\/ndt\/gfm088","article-title":"Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors","volume":"22","author":"Pascual","year":"2007","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.trim.2022.101774_bb0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s13737-016-0036-1","article-title":"Matched-pair analysis: identification of factors with independent influence on the development of PTLD after kidney or liver transplantation","author":"Rausch","year":"2016","journal-title":"Transp. Res."},{"issue":"1","key":"10.1016\/j.trim.2022.101774_bb0105","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1046\/j.1600-6135.2003.00274.x","article-title":"Immunosuppression and the risk of post-transplant malignancy among cadaveric first kidney transplant recipients","volume":"4","author":"Bustami","year":"2004","journal-title":"Am. J. Transplant."},{"issue":"9","key":"10.1016\/j.trim.2022.101774_bb0110","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1097\/01.tp.0000179639.98338.39","article-title":"Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression","volume":"80","author":"Caillard","year":"2005","journal-title":"Transplantation."},{"issue":"9","key":"10.1016\/j.trim.2022.101774_bb0115","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1111\/tri.12375","article-title":"CNI withdrawal for post-transplant lymphoproliferative disorders in kidney transplant is an independent risk factor for graft failure and mortality","volume":"27","author":"Rabot","year":"2014","journal-title":"Transpl. Int."},{"issue":"5","key":"10.1016\/j.trim.2022.101774_bb0120","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1093\/ndt\/gfx356","article-title":"Incidence and predictors of post-transplant lymphoproliferative disease after kidney transplantation during adulthood and childhood: a registry study","volume":"33","author":"Francis","year":"2018","journal-title":"Nephrol. Dial. Transplant."},{"issue":"11","key":"10.1016\/j.trim.2022.101774_bb0125","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1111\/ajt.13830","article-title":"Long-term outcomes in belatacept- versus cyclosporine-treated recipients of extended criteria donor kidneys: final results from BENEFIT-EXT, a phase III randomized study","volume":"16","author":"Durrbach","year":"2016","journal-title":"Am. J. Transplant."},{"issue":"11","key":"10.1016\/j.trim.2022.101774_bb0130","doi-asserted-by":"crossref","first-page":"3479","DOI":"10.3390\/jcm9113479","article-title":"Opportunistic infections and efficacy following conversion to belatacept-based therapy after kidney transplantation: a French multicenter cohort","volume":"9","author":"Bertrand","year":"2020","journal-title":"J. Clin. Med."},{"issue":"3","key":"10.1016\/j.trim.2022.101774_bb0135","first-page":"320","article-title":"No increased risk of posttransplant lymphoproliferative disorder following alemtuzumab induction in kidney transplant","volume":"17","author":"Oliver","year":"2019","journal-title":"Experiment. Clin. Transplant. Off. J. Middle East Soc. Organ Transplant."},{"key":"10.1016\/j.trim.2022.101774_bb0140","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/1744666X.2019.1574570","article-title":"Belatacept in kidney transplantation and its limitations","volume":"15","author":"Noble","year":"2019","journal-title":"Expert. Rev. Clin. Immunol."},{"key":"10.1016\/j.trim.2022.101774_bb0145","doi-asserted-by":"crossref","first-page":"g6679","DOI":"10.1136\/bmj.g6679","article-title":"Effect of sirolimus on malignancy and survival after kidney transplantation: systematic review and meta-analysis of individual patient data","volume":"349","author":"Knoll","year":"2014","journal-title":"BMJ"},{"issue":"8","key":"10.1016\/j.trim.2022.101774_bb0150","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1093\/ndt\/gfh884","article-title":"Resolution of renal allograft-associated post-transplant lymphoproliferative disorder with the introduction of sirolimus","volume":"20","author":"Zaltzman","year":"2005","journal-title":"Nephrol. Dial. Transplant."},{"issue":"5","key":"10.1016\/j.trim.2022.101774_bb0155","doi-asserted-by":"crossref","DOI":"10.1053\/j.ajkd.2006.01.029","article-title":"Sirolimus-induced remission of posttransplantation lymphoproliferative disorder","volume":"47","author":"Cullis","year":"2006","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.trim.2022.101774_bb0160","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1007\/s11899-013-0162-5","article-title":"Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies","volume":"8","author":"Al-Mansour","year":"2013","journal-title":"Curr. Hematol. Malig. Rep."},{"issue":"3","key":"10.1016\/j.trim.2022.101774_bb0165","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.trim.2015.04.003","article-title":"Rabbit antithymocyte globulin induction and risk of post-transplant lymphoproliferative disease in adult and pediatric solid organ transplantation: an update","volume":"32","author":"Hertig","year":"2015","journal-title":"Transpl. Immunol."},{"issue":"6","key":"10.1016\/j.trim.2022.101774_bb0170","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1097\/01.TP.0000173770.42403.F7","article-title":"Low incidence of malignancy among sirolimus\/cyclosporine-treated renal transplant recipients","volume":"80","author":"Kahan","year":"2005","journal-title":"Transplantation."},{"issue":"5","key":"10.1016\/j.trim.2022.101774_bb0175","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1016\/j.transproceed.2021.04.020","article-title":"Heterogeneous manifestations of posttransplant lymphoma in renal transplant recipients: a case series","volume":"53","author":"Patil","year":"2021","journal-title":"Transplant. Proc."},{"key":"10.1016\/j.trim.2022.101774_bb0180","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1097\/TP.0b013e31823ae7db","article-title":"Association of immunosuppressive maintenance regimens with posttransplant lymphoproliferative disorder in kidney transplant recipients","volume":"93","author":"Sampaio","year":"2012","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.trim.2022.101774_bb0185","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1034\/j.1600-6143.2003.00078.x","article-title":"Sirolimus prolongs recovery from delayed graft function after cadaveric renal transplantation","volume":"3","author":"McTaggart","year":"2003","journal-title":"Am. J. Transplant."},{"issue":"8","key":"10.1016\/j.trim.2022.101774_bb0190","doi-asserted-by":"crossref","first-page":"1913","DOI":"10.1097\/TP.0000000000001409","article-title":"Delayed graft function phenotypes and 12-month kidney transplant outcomes","volume":"101","author":"Hall","year":"2017","journal-title":"Transplantation."},{"key":"10.1016\/j.trim.2022.101774_bb0195","doi-asserted-by":"crossref","DOI":"10.1111\/ajt.17021","article-title":"Chronic immunosuppression, cancer Spanish consortium. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation","author":"Rodr\u00edguez-Per\u00e1lvarez","year":"2022","journal-title":"Am. J. Transplant."},{"issue":"12","key":"10.1016\/j.trim.2022.101774_bb0200","doi-asserted-by":"crossref","first-page":"2954","DOI":"10.1111\/j.1600-6143.2005.01125.x","article-title":"Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil","volume":"5","author":"Robson","year":"2005","journal-title":"Am. J. Transplant."},{"issue":"3","key":"10.1016\/j.trim.2022.101774_bb0205","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1182\/blood-2009-02-202507","article-title":"Immunosuppression and other risk factors for early and late non-Hodgkin lymphoma after kidney transplantation","volume":"114","author":"van Leeuwen","year":"2009","journal-title":"Blood."},{"issue":"2","key":"10.1016\/j.trim.2022.101774_bb0210","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ajkd.2021.01.015","article-title":"Posttransplant lymphoproliferative disorder following kidney transplantation: a review","volume":"78","author":"Sprangers","year":"2021","journal-title":"Am. J. Kidney Dis."},{"key":"10.1016\/j.trim.2022.101774_bb0215","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1038\/sj.leu.2404683","article-title":"Mechanisms of action of antithymocyte globulin: T-cell depletion and beyond","volume":"21","author":"Mohty","year":"2007","journal-title":"Leukemia"},{"issue":"5","key":"10.1016\/j.trim.2022.101774_bb0220","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1016\/j.transproceed.2011.03.036","article-title":"Posttransplantation lymphoproliferative disorder in kidney and heart transplant recipients receiving thymoglobulin: a systematic review","volume":"43","author":"Marks","year":"2011","journal-title":"Transplant. Proc."},{"issue":"9","key":"10.1016\/j.trim.2022.101774_bb0225","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1111\/tri.13982","article-title":"Risk factors for Epstein-Barr virus reactivation after renal transplantation: results of a large, multi-Centre study","volume":"34","author":"Blazquez-Navarro","year":"2021","journal-title":"Transpl. Int."},{"key":"10.1016\/j.trim.2022.101774_bb0230","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1146\/annurev.immunol.15.1.405","article-title":"Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection","volume":"15","author":"Rickinson","year":"1997","journal-title":"Annu. Rev. Immunol."},{"issue":"7","key":"10.1016\/j.trim.2022.101774_bb0235","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM200008173430707","article-title":"Epstein-Barr virus infection","volume":"343","author":"Cohen","year":"2000","journal-title":"N. Engl. J. Med."},{"issue":"6","key":"10.1016\/j.trim.2022.101774_bb0240","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.1998.16.6.2052","article-title":"Posttransplant lymphoproliferative disorders not associated with Epstein-Barr virus: a distinct entity?","volume":"16","author":"Leblond","year":"1998","journal-title":"J. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.trim.2022.101774_bb0245","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1111\/j.1399-3046.2005.00361.x","article-title":"Risk for post-transplant lymphoproliferative disorder after polyclonal antibody induction in kidney transplantation","volume":"9","author":"Dharnidharka","year":"2005","journal-title":"Pediatr. Transplant."},{"issue":"7","key":"10.1016\/j.trim.2022.101774_bb0250","doi-asserted-by":"crossref","first-page":"2971","DOI":"10.1093\/ndt\/gfr769","article-title":"Impact of Epstein-Barr virus donor and recipient serostatus on the incidence of post-transplant lymphoproliferative disorder in kidney transplant recipients","volume":"27","author":"Sampaio","year":"2012","journal-title":"Nephrol. Dial. Transplant."},{"issue":"10","key":"10.1016\/j.trim.2022.101774_bb0255","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1034\/j.1600-6143.2002.21019.x","article-title":"Post-transplant lymphoproliferative disorder in the United States: young Caucasian males are at highest risk","volume":"2","author":"Dharnidharka","year":"2002","journal-title":"Am. J. Transplant."},{"issue":"1","key":"10.1016\/j.trim.2022.101774_bb0260","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1177\/107424840601100107","article-title":"Post-transplantation lymphoproliferative disorder in heart and kidney transplant patients: a single-center experience","volume":"11","author":"Wasson","year":"2006","journal-title":"J. Cardiovasc. Pharmacol. Ther."}],"container-title":["Transplant Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002489?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0966327422002489?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,18]],"date-time":"2025-10-18T18:03:28Z","timestamp":1760810608000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0966327422002489"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":52,"alternative-id":["S0966327422002489"],"URL":"https:\/\/doi.org\/10.1016\/j.trim.2022.101774","relation":{},"ISSN":["0966-3274"],"issn-type":[{"value":"0966-3274","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Short-term decreased post transplant lymphoproliferative disorder risk after kidney transplantation using two novel regimens","name":"articletitle","label":"Article Title"},{"value":"Transplant Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.trim.2022.101774","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"101774"}}